Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
AddLife AB ( ($SE:ALIF.B) ) just unveiled an announcement.
AddLife AB has acquired Pharmacold A/S, a Danish specialist in refrigeration technology for the pharmaceutical and healthcare sectors. This acquisition, which aligns with AddLife’s strategic goals, will enhance its service offerings and market position in Denmark. Pharmacold will operate as a subsidiary under Holm & Halby, a company within AddLife’s Labtech business area. The acquisition is expected to have a marginally positive impact on AddLife’s earnings per share for the current financial year.
The most recent analyst rating on ($SE:ALIF.B) stock is a Hold with a SEK200.00 price target. To see the full list of analyst forecasts on AddLife AB stock, see the SE:ALIF.B Stock Forecast page.
More about AddLife AB
AddLife is an independent partner in the Life Science industry, providing high-quality products, services, and advice to both private and public sectors across Europe. The company operates with 2,300 employees in about 85 subsidiaries, generating net sales exceeding SEK 10 billion. AddLife shares are listed on Nasdaq Stockholm.
YTD Price Performance: 38.21%
Average Trading Volume: 80,974
Technical Sentiment Signal: Strong Buy
Current Market Cap: SEK23.05B
Learn more about ALIF.B stock on TipRanks’ Stock Analysis page.